Background: Components of the antioxidant defense system in Trypanosoma cruzi are potential targets for new drug development. Superoxide dismutases (SODs) constitute key components of antioxidant defense systems, removing excess superoxide anions by converting them into oxygen and hydrogen peroxide. The main goal of the present study was to investigate the genes coding for iron superoxide dismutase (FeSOD) in T. cruzi strains from an evolutionary perspective.
Methods: In this study, molecular biology methods and phylogenetic studies were combined with drug assays. The FeSOD-A and FeSOD-B genes of 35 T. cruzi strains, belonging to six discrete typing units (Tcl-TcVI), from different hosts and geographical regions were amplified by PCR and sequenced using the Sanger method. Evolutionary trees were reconstructed based on Bayesian inference and maximum likelihood methods. Drugs that potentially interacted with T. cruzi FeSODs were identified and tested against the parasites.
Results: Our results suggest that T. cruzi FeSOD types are members of distinct families. Gene copies of FeSOD-A (n = 2), FeSOD-B (n = 4) and FeSOD-C (n = 4) were identified in the genome of the T. cruzi reference clone CL Brener. Phylogenetic inference supported the presence of two functional variants of each FeSOD type across the T. cruzi strains. Phylogenetic trees revealed a monophyletic group of FeSOD genes of T. cruzi TcIV strains in both distinct genes. Altogether, our results support the hypothesis that gene duplication followed by divergence shaped the evolution of T. cruzi FeSODs. Two drugs, mangafodipir and polaprezinc, that potentially interact with T. cruzi FeSODs were identified and tested in vitro against amastigotes and trypomastigotes: mangafodipir had a low trypanocidal effect and polaprezinc was inactive.
Conclusions: Our study contributes to a better understanding of the molecular biodiversity of T. cruzi FeSODs. Herein we provide a successful approach to the study of gene/protein families as potential drug targets.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169349 | PMC |
| http://dx.doi.org/10.1186/s13071-022-05319-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets.
Expert Opin Ther Targets
October 2023
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
Introduction: Chagas disease (CD) imposes social and economic burdens, yet the available treatments have limited efficacy in the disease's chronic phase and cause serious adverse effects. To address this challenge, target-based approaches are a possible strategy to develop new, safe, and active treatments for both phases of the disease.
Areas Covered: This review delves into target-based approaches applied to CD drug discovery, emphasizing the studies from the last five years.
Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations.
Parasit Vectors
May 2023
Genômica Funcional de Parasitos, Instituto René Rachou (IRR/Fiocruz Minas), Av. Augusto de Lima 1715, Belo Horizonte, MG, CEP 30190-002, Brazil.
Background: Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is a serious public health concern in Latin America. Nifurtimox and benznidazole (BZ), the only two drugs currently approved for the treatment of CD, have very low efficacies in the chronic phase of the disease and several toxic side effects. Trypanosoma cruzi strains that are naturally resistant to both drugs have been reported.
View Article and Find Full Text PDFIdentification of Aryl Polyamines Derivatives as Anti- Agents Targeting Iron Superoxide Dismutase.
Pharmaceutics
December 2022
Department of Parasitology, University of Granada, Severo Ochoa s/n, 18071 Granada, Spain.
Chagas disease (CD) is a tropical and potentially fatal infection caused by . Although CD was limited to Latin America as a silent disease, CD has become widespread as a result of globalization. Currently, 6-8 million people are infected worldwide, and no effective treatment is available.
View Article and Find Full Text PDFTrypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.
Parasit Vectors
June 2022
René Rachou Institute, Oswaldo Cruz Foundation (Functional genomics of parasites group; Biosystems informatics, bioengineering and genomic group), Belo Horizonte, Minas Gerais, Brazil.
Background: Components of the antioxidant defense system in Trypanosoma cruzi are potential targets for new drug development. Superoxide dismutases (SODs) constitute key components of antioxidant defense systems, removing excess superoxide anions by converting them into oxygen and hydrogen peroxide. The main goal of the present study was to investigate the genes coding for iron superoxide dismutase (FeSOD) in T.
View Article and Find Full Text PDFIn vitro Leishmanicidal and Trypanosomicidal Properties of Imidazole-Containing Azine and Benzoazine Derivatives.
ChemMedChem
December 2021
Departamento de Química Orgánica, Facultad de Química, Universidad Complutense, 28040, Madrid, Spain.
Leishmaniasis and Chagas diseases are two of the most important parasitic diseases in the world. Both belong to the category of Neglected Tropical Diseases, and they cannot be prevented by vaccination. Their treatments are founded in outdated drugs that possess many pernicious side-effects and they're not easy to administer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!